News & Views
Investment to accelerate delivery of biologics and medicines in China
Jan 25 2016
AstraZeneca, along with MedImmune, its global biologics research and development arm, has undertaken strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines locally in China. A strategic alliance with WuXi AppTec, a leading Chinese biologics manufacturer and CRO, brings the option for AstraZeneca to acquire WuXi AppTec’s biologics manufacturing capacity in Wuxi City in the next few years through an overall investment approximating $100 million. Prior to that, Wuxi AppTec remains the company’s exclusive partner for R&D manufacturing for innovative biologics in China. The alliance builds on the existing joint venture between MedImmune and WuXi AppTec to develop and commercialise MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.
An investment of $50 million will help to build an additional development and launch facility alongside the existing manufacturing site in Wuxi City to support the development and manufacture of innovative small molecules discovered in China and other global R&D sites.
Additional investments also include the creation of a new global hub for Pharmaceutical Development – alongside those in the UK and Sweden - with up to 50 scientists based in Shanghai and Wuxi City, to support both China and global needs. AstraZeneca is also establishing an integrated China medicines development organisation, bringing together early and late-stage medicines development across small molecules and biologics.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia